Naoto Morikawa

2.0k total citations · 1 hit paper
47 papers, 1.5k citations indexed

About

Naoto Morikawa is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Naoto Morikawa has authored 47 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 21 papers in Molecular Biology and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Naoto Morikawa's work include Lung Cancer Research Studies (23 papers), Lung Cancer Treatments and Mutations (20 papers) and Cancer therapeutics and mechanisms (10 papers). Naoto Morikawa is often cited by papers focused on Lung Cancer Research Studies (23 papers), Lung Cancer Treatments and Mutations (20 papers) and Cancer therapeutics and mechanisms (10 papers). Naoto Morikawa collaborates with scholars based in Japan, United States and Greece. Naoto Morikawa's co-authors include Akira Inoue, Toshihiro Nukiwa, Makoto Maemondo, Tatsuro Fukuhara, Yasuo Saijo, Yuichiro Kimura, Hiroshi Watanabe, Takuji Suzuki, John V. Heymach and Jing Wang and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Naoto Morikawa

42 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

2019 616 citations Triparna Sen, B. Leticia Rodriguez et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Naoto Morikawa

Since Specialization

Citations

This map shows the geographic impact of Naoto Morikawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoto Morikawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoto Morikawa more than expected).

Fields of papers citing papers by Naoto Morikawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoto Morikawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoto Morikawa. The network helps show where Naoto Morikawa may publish in the future.

Co-authorship network of co-authors of Naoto Morikawa

This figure shows the co-authorship network connecting the top 25 collaborators of Naoto Morikawa. A scholar is included among the top collaborators of Naoto Morikawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoto Morikawa. Naoto Morikawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Development of a national health policy logic model to accelerate the integration of oncology and palliative care: a nationwide Delphi survey in Japan 2022 ·International Journal of Clinical Oncology ·Yu Uneno, Maki Iwai, Naoto Morikawa, Keita Tagami, Yōko Matsumoto, (unknown), Takaomi Kessoku, Tatsunori Shimoi, Miyuki Yoshida, Aya Miyoshi, (unknown), (unknown), (unknown), Akemi Yamagishi, Tatsuya Morita, Akira Inoue, Manabu Muto	1
2	Phase II study of carboplatin–paclitaxel alone or with bevacizumab in advanced sarcomatoid carcinoma of the lung: HOT1201/NEJ024 2022 ·International Journal of Clinical Oncology ·Satoshi Oizumi, Kei Takamura, Toshiyuki Harada, Motoko Tachihara, Naoto Morikawa, Ryoichi Honda, Satoshi Watanabe, Tetsuhiko Asao, (unknown), Tatsuro Fukuhara, Rintaro Noro, Eiki Kikuchi, Yasuhiro Tsutani, (unknown), Kunihiko Kobayashi, Hirotoshi Dosaka‐Akita	6
3	Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers 2021 ·Journal of Biological Chemistry ·Jayanthi Gudikote, Tina Cascone, Alissa Poteete, Piyada Sitthideatphaiboon, Qiuyu Wu, Naoto Morikawa, Fahao Zhang, Shaohua Peng, Pan Tong, Lerong Li, Li Shen, Monique B. Nilsson, Philip H. Jones, Erik P. Sulman, Jing Wang, Jean‐Christophe Bourdon, Faye M. Johnson, John V. Heymach	26
4	Randomized phase II trial of carboplatin + nab-paclitaxel versus cisplatin + gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302 2020 ·International Journal of Clinical Oncology ·Yosuke Kawashima, Toshiyuki Harada, Yuka Fujita, Taku Nakagawa, Kana Watanabe, Naoto Morikawa, Kei Takamura, Kenya Kanazawa, (unknown), Kazuhiro Usui, Akimasa Sekine, Akira Inoue, Shunichi Sugawara	3
5	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer breakdown → 2019 ·Cancer Discovery ·Triparna Sen, B. Leticia Rodriguez, Limo Chen, Carminia Maria Della Corte, Naoto Morikawa, Junya Fujimoto, Sandra Cristea, Thuyen Nguyen, Lixia Diao, Lerong Li, You-Hong Fan, Yongbin Yang, Jing Wang, Bonnie S. Glisson, Ignacio I. Wistuba, Julien Sage, John V. Heymach, Don L. Gibbons, Lauren A. Byers	616
6	Design of Self-Assembling Molecules and Boundary Value Problem for Flows on a Space of <i>n</i>-Simplices 2019 ·Applied Mathematics ·Naoto Morikawa	1
7	P1.01-08 Randomized Phase II Trial of CBDCA+nab-PTX vs CDDP+GEM in Patients with Chemo-Naïve Squamous Cell Lung Cancer: NJLCG1302 2019 ·Journal of Thoracic Oncology ·Toshiyuki Harada, Yosuke Kawashima, Yasuko Fujita, Taku Nakagawa, Kana Watanabe, Naoto Morikawa, Kei Takamura, Kenya Kanazawa, (unknown), Kazuhiro Usui, Akira Inoue, Akimasa Sekine, Shunichi Sugawara	2
8	Elemental and mutational analysis of lung tissue in lung adenocarcinoma patients 2019 ·Translational Lung Cancer Research ·Ryosuke Chiba, Naoto Morikawa, K. Sera, Kazuyuki Ishida, Hiromi Nagashima, (unknown), Hiroyuki Deguchi, (unknown), (unknown), Hajime Saito, Tamotsu Sugai, Kohei Yamauchi, Makoto Maemondo	9
9	Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab 2018 ·Cancer Chemotherapy and Pharmacology ·(unknown), Junya Sato, Toshiyuki Harada, Shoichi Kuyama, Toshiro Suzuki, (unknown), Yoshitaka Saito, (unknown), (unknown), (unknown), Masami Tsuchiya, (unknown), (unknown), Takeshi Chiba, Kenzo Kudo, Satoshi Oizumi, Akira Inoue, Naoto Morikawa	10
10	Global Geometrical Constraints on the Shape of Proteins and Their Influence on Allosteric Regulation 2018 ·Applied Mathematics ·Naoto Morikawa	4
11	Discrete Differential Geometry and the Structural Study of Protein Complexes 2017 ·Naoto Morikawa	4
12	Case series on the association between blood levels and side effects of afatinib maleate 2017 ·Cancer Chemotherapy and Pharmacology ·Junya Sato, Naoto Morikawa, Ryosuke Chiba, (unknown), (unknown), (unknown), Kohei Yamauchi, Kenzo Kudo	5
13	Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901 2017 ·Lung Cancer ·Naoto Morikawa, Akira Inoue, Shunichi Sugawara, Makoto Maemondo, Toshiyuki Harada, Masao Harada, Yuka Fujita, (unknown), Hiroshi Yokouchi, Hiroshi Watanabe, Kazuhiro Usui, Toshiro Suzuki, Jun Sakakibara‐Konishi, Hiroki Nagai, (unknown), Toshihiro Nukiwa	6
14	Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor 2016 ·Cancer Chemotherapy and Pharmacology ·Masahito Ogasawara, Yutaka Nakamura, Naoto Morikawa, (unknown), (unknown), Ryosuke Chiba, (unknown), Mika Ohta, Tatsuo Tanita, Tamotsu Sugai, Kazutaka Maeyama, Kohei Yamauchi, Yutaka Takaoka	6
15	Feasibility study of short hydration using oral rehydration solution in cisplatin including chemotherapy of lung cancer 2016 ·Journal of Pharmaceutical Health Care and Sciences ·Junya Sato, Naoto Morikawa, (unknown), Hiromi Nagashima, (unknown), (unknown), Kenzo Kudo	6
16	First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies 2015 ·Expert Opinion on Pharmacotherapy ·Naoto Morikawa, Yuji Minegishi, Akira Inoue, Makoto Maemondo, Kunihiko Kobayashi, Shunichi Sugawara, Masao Harada, Koichi Hagiwara, Shoji Okinaga, Satoshi Oizumi, Toshihiro Nukiwa, Akihiko Gemma	23
17	Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702 2015 ·Lung Cancer ·Akira Inoue, Shunichi Sugawara, Makoto Maemondo, Yoshiaki Mori, Satoshi Oizumi, Masao Harada, Kageaki Taima, Naoto Morikawa, Takashi Ishida, Ichiro Kinoshita, Hiroshi Watanabe, Toshiro Suzuki, Taku Nakagawa, Ryota Saito, Toshihiro Nukiwa	25
18	Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802 2014 ·Respiratory Investigation ·Yosuke Kawashima, Akira Inoue, Shunichi Sugawara, Satoshi Oizumi, Makoto Maemondo, (unknown), Toshiro Suzuki, Kazuhiro Usui, Masao Harada, Naoto Morikawa, Yukihiro Hasegawa, Ryota Saito, Osamu Ishimoto, Tomohiro Sakakibara, Hajime Asahina, Toshihiro Nukiwa	3
19	First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study 2012 ·Journal of Thoracic Oncology ·Makoto Maemondo, Yuji Minegishi, Akira Inoue, Kunihiko Kobayashi, Masao Harada, Shoji Okinaga, Naoto Morikawa, Satoshi Oizumi, Tomoaki Tanaka, Hiroshi Isobe, Shoji Kudoh, Koichi Hagiwara, Toshihiro Nukiwa, (unknown)	118
20	Large‐cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: Possible transformation of lung adenocarcinoma 2012 ·Respirology ·Satoru Yanagisawa, Naoto Morikawa, Yuichiro Kimura, (unknown), Kazuhiro Murakami, Toshiharu Tabata	20

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact